NR1I3 and type 2 diabetes mellitus: Furthermore, rutaecarpine and evodiamine were able to suppress gluconeogenesis and lipogenesis through their activation of the constitutive androstane receptor (CAR) in vitro and vivo, thus having a therapeutic potential for the treatment of hyperglycemia and type 2 diabetes [195].